Aclaris Therapeutics (ACRS)
(Delayed Data from NSDQ)
$1.22 USD
-0.02 (-1.61%)
Updated Aug 6, 2024 04:00 PM ET
After-Market: $1.28 +0.06 (4.92%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for Aclaris Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 119 | 218 | 191 | 54 | 75 |
Receivables | 0 | 0 | 1 | 1 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 9 | 14 | 13 | 3 | 8 |
Total Current Assets | 129 | 232 | 205 | 57 | 84 |
Net Property & Equipment | 2 | 1 | 1 | 2 | 2 |
Investments & Advances | 63 | 12 | 34 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 7 | 7 | 7 | 7 |
Deposits & Other Assets | 4 | 3 | 4 | 5 | 5 |
Total Assets | 197 | 255 | 251 | 71 | 98 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 9 | 10 | 10 | 5 | 10 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 19 | 9 | 10 | 6 | 8 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2 | 2 | 2 | 3 | 4 |
Total Current Liabilities | 31 | 22 | 23 | 15 | 22 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 1 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 11 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 9 | 35 | 31 | 7 | 5 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 40 | 57 | 54 | 33 | 28 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 928 | 881 | 793 | 542 | 524 |
Retained Earnings | -771 | -682 | -595 | -505 | -454 |
Other Equity | 0 | -1 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 157 | 198 | 197 | 38 | 70 |
Total Liabilities & Shareholder's Equity | 197 | 255 | 251 | 71 | 98 |
Total Common Equity | 157 | 198 | 197 | 38 | 70 |
Shares Outstanding | 70.80 | 66.60 | 61.20 | 42.90 | 41.30 |
Book Value Per Share | 2.22 | 2.97 | 3.22 | 0.88 | 1.69 |
Fiscal Year End for Aclaris Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 128 | 119 | 103 | 120 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 7 | 9 | 20 | 13 |
Total Current Assets | NA | 135 | 129 | 123 | 133 |
Net Property & Equipment | NA | 2 | 2 | 2 | 2 |
Investments & Advances | NA | 33 | 63 | 84 | 91 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 7 | 7 |
Deposits & Other Assets | NA | 4 | 4 | 3 | 3 |
Total Assets | NA | 174 | 197 | 218 | 236 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 11 | 9 | 10 | 11 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 7 | 19 | 15 | 9 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 3 | 2 | 2 | 2 |
Total Current Liabilities | NA | 20 | 31 | 27 | 23 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 9 | 34 | 33 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 32 | 40 | 62 | 56 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 930 | 928 | 927 | 921 |
Retained Earnings | NA | -788 | -771 | -769 | -740 |
Other Equity | NA | 0 | 0 | -1 | -1 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 142 | 157 | 156 | 180 |
Total Liabilities & Shareholder's Equity | NA | 174 | 197 | 218 | 236 |
Total Common Equity | 0 | 142 | 157 | 156 | 180 |
Shares Outstanding | 71.20 | 71.20 | 70.80 | 70.80 | 70.60 |
Book Value Per Share | 0.00 | 1.99 | 2.22 | 2.21 | 2.55 |